Renal & Urinary

Postrenal AKI: obstruction workup and decompression

Clinical Overview and When to Suspect Postrenal AKI

— Older man with rising creatinine, nocturia, weak stream, hesitancy, or palpable suprapubic fullness

— Woman with cervical/ovarian cancer, endometriosis, or prior pelvic radiation/surgery presenting with AKI

— Anuria or wildly fluctuating urine output (intermittent total obstruction)

— AKI with bland urine sediment and no clear prerenal or intrinsic etiology

— Flank pain + AKI in a patient with one kidney, transplant, or known stones

— New AKI after pelvic surgery (think ureteral injury)

— <1 week obstruction: full recovery expected

— 1–4 weeks: partial recovery

— >12 weeks: largely irreversible fibrosis

Definition: Acute kidney injury (AKI) caused by mechanical obstruction of urinary outflow anywhere from renal pelvis to urethral meatus, leading to elevated intratubular pressure, decreased GFR, and—if unrelieved—tubular atrophy and irreversible nephron loss.

Epidemiology: Accounts for ~5–10% of all AKI in adults but a disproportionate share in elderly men (BPH, prostate cancer) and in patients with pelvic malignancy, retroperitoneal disease, single functioning kidney, or neurogenic bladder.

When to suspect in the outpatient or ED setting:

Pathophysiology pearl: Bilateral upper-tract obstruction (or unilateral in a solitary kidney) is required to cause AKI; unilateral obstruction with a normal contralateral kidney rarely raises creatinine but still risks ipsilateral nephron loss.

Timeline of reversibility:

Board pearl: Any unexplained AKI in an elderly man must prompt a bladder scan or post-void residual (PVR) before extensive intrinsic workup—BPH-driven retention is the single most common reversible cause of postrenal AKI on Step 3.

Step 3 management: First decision point is always "Is the bladder full?" If PVR >300 mL → Foley immediately; if empty → image upper tracts with renal/bladder ultrasound to exclude hydronephrosis.

Presentation Patterns and Key History

— BPH: gradual hesitancy, weak stream, nocturia, incomplete emptying, dribbling, overflow incontinence

— Urethral stricture: prior STI, instrumentation, catheter trauma, pelvic radiation

— Bladder neck obstruction, prostate cancer, anticholinergic/opioid medications causing acute retention

— Neurogenic bladder: diabetes, MS, spinal cord injury, prior pelvic surgery

— Nephrolithiasis: sudden severe colicky flank pain radiating to groin, nausea, hematuria

— Malignancy (cervical, prostate, bladder, colorectal, retroperitoneal lymphoma): subacute flank discomfort, weight loss, B-symptoms

— Retroperitoneal fibrosis: vague back/flank pain, often IgG4-related, may follow methysergide or ergot use

— Papillary necrosis: sickle cell, analgesic nephropathy, diabetes, pyelonephritis—sloughed papillae obstruct ureter

— Iatrogenic ureteral ligation after hysterectomy/colorectal surgery

— Anuria alternating with polyuria → intermittent complete obstruction

— Fever + flank pain + AKI → obstructed infected system (urosepsis)—surgical emergency

— Gross hematuria + clots → clot retention or bladder/upper-tract tumor

— Constitutional symptoms → malignancy or retroperitoneal disease

Lower tract obstruction (most common):

Upper tract obstruction:

Pregnancy-related: Gravid uterus compressing ureters (typically right > left after 20 weeks)

Symptom red flags to elicit:

Medication review (high-yield Step 3): Anticholinergics (oxybutynin, TCAs, antihistamines), opioids, sympathomimetics (pseudoephedrine), and recent contrast can precipitate acute retention especially in men with baseline BPH.

Key distinction: Polyuria of postobstructive diuresis (after relief) vs. polyuria of intrinsic tubular disease—the former follows decompression and resolves with appropriate volume management; failure to recognize causes hypovolemic collapse.

Board pearl: The classic "AKI in a patient with cervical cancer" stem = bilateral ureteral encasement → bilateral hydronephrosis → urgent percutaneous nephrostomy.

Physical Exam Findings and Hemodynamic Assessment

— Hypertension is common (volume retention, RAAS activation)

— Fever raises concern for obstructed pyelonephritis → urgent decompression

— Hypotension + obstruction + fever = urosepsis, ICU territory

— Suprapubic dullness, tenderness, or palpable bladder dome above pubis suggests >500 mL retention

— CVA tenderness with hydronephrosis or pyelonephritis

— Palpable flank mass in massive hydronephrosis or renal mass

— Digital rectal exam: enlarged, smooth prostate (BPH) vs. nodular/asymmetric (cancer); boggy/tender (prostatitis)

— Phimosis, meatal stenosis, palpable urethral stricture

— In women: pelvic exam for cervical mass, fixed adnexal mass, procidentia/uterine prolapse compressing ureters

— Saddle anesthesia, decreased rectal tone, lower-extremity weakness → cauda equina as cause of neurogenic retention—emergency MRI

— Diabetic autonomic neuropathy: orthostasis with chronic retention

— Often euvolemic or hypervolemic (edema, elevated JVP, crackles)

— Anuric patient with full bladder = retention until proven otherwise

— After decompression, monitor for orthostasis from postobstructive diuresis

Vital signs:

Abdominal/pelvic exam:

Genitourinary exam (do not skip on Step 3):

Neurologic exam:

Volume status:

Bedside maneuver: A bladder scanner (or bedside ultrasound) showing >300 mL post-void volume is essentially diagnostic of functional outlet obstruction; pair with renal ultrasound for upper tracts.

CCS pearl: In a CCS case, order "bladder scan" or "post-void residual" in the first set of orders alongside BMP and urinalysis when AKI is present in an elderly patient—skipping this delays Foley placement and costs the case.

Board pearl: A distended bladder that is not tender suggests chronic retention with detrusor decompensation; a tender distended bladder suggests acute retention—both need drainage but the former is at higher risk for postobstructive diuresis and hematuria ex vacuo.

Diagnostic Workup — Initial Labs, Imaging, and Bedside Tests

— BMP: creatinine, BUN, K⁺ (watch for hyperkalemia), bicarbonate (non-anion-gap metabolic acidosis from type 4 RTA pattern or distal RTA in chronic obstruction)

— CBC: leukocytosis suggests infection

— Urinalysis with microscopy: typically bland sediment; hematuria suggests stone/tumor; pyuria + bacteriuria suggests infection

— Urine culture if any suspicion of UTI

— Coagulation studies if intervention anticipated

— Early obstruction: FeNa <1% (prerenal-like)

— Prolonged obstruction (>24–48h): FeNa >2% (tubular dysfunction)

— Key distinction: Urine indices cannot distinguish postrenal AKI reliably—imaging is required.

— >300 mL → place Foley catheter immediately

— Document pre- and post-catheterization urine volume (>400 mL on initial drainage confirms retention)

— Sensitivity ~90% for hydronephrosis; specificity high

— Look for hydronephrosis, hydroureter, bladder distension, post-void residual, stones, masses

— False negatives: Early obstruction (<24 h), volume-depleted patient, retroperitoneal fibrosis encasing ureters without dilation, staghorn calculi

Core labs (order simultaneously):

Urine indices (less useful but tested):

Bedside bladder scan / PVR:

Renal and bladder ultrasound (first-line imaging):

ECG: Mandatory if K⁺ >6 or any AKI with symptoms (peaked T waves, widened QRS).

CCS pearl: Sequence is bladder scan → Foley if retained → renal ultrasound if creatinine still elevated or upper-tract obstruction suspected. Ordering CT before ultrasound in straightforward retention is wasteful and may be penalized.

Board pearl: Negative ultrasound does not exclude obstruction in a dehydrated patient or in retroperitoneal fibrosis/malignant encasement—if clinical suspicion persists, get CT or MR urography.

Step 3 management: Recheck BMP 6–12 hours after Foley placement; a falling creatinine confirms postrenal etiology.

Diagnostic Workup — Advanced and Confirmatory Studies

— Gold standard for nephrolithiasis (sensitivity/specificity >95%)

— Identifies size, location, and degree of obstruction; perinephric stranding suggests inflammation

— Stones ≥10 mm or proximal ureteral stones unlikely to pass spontaneously → urology referral

— Evaluates urothelial malignancy, ureteral strictures, extrinsic compression

— Indicated for unexplained hematuria + obstruction, suspected upper-tract tumor

— Pregnancy, contrast allergy, severe CKD where iodinated contrast is risky

— Good for retroperitoneal fibrosis (T2 signal characteristics) and pediatric evaluation

— Differentiates obstructive vs. non-obstructive hydronephrosis (e.g., chronic dilation without functional obstruction)

— Quantifies split renal function—critical before nephrectomy decisions

— Performed by urology/IR at time of stent or nephrostomy placement

— Defines exact level and length of ureteral lesion

— Evaluates urethra, prostate, bladder for stricture, tumor, foreign body

— Allows stent placement

— Reflux, posterior urethral valves (pediatric), neurogenic bladder evaluation

— Outpatient evaluation of detrusor function vs. outlet obstruction in chronic retention

Non-contrast CT abdomen/pelvis (CT KUB):

CT urography (with contrast):

MR urography:

Renal scintigraphy (MAG3 with furosemide/diuretic renogram):

Retrograde or antegrade pyelography:

Cystoscopy:

Voiding cystourethrogram (VCUG):

Urodynamics:

Key distinction: Hydronephrosis on imaging ≠ functional obstruction. Causes of non-obstructive hydronephrosis include vesicoureteral reflux, post-relief residual dilation, parapelvic cysts, and pregnancy—diuretic renogram resolves the question.

Board pearl: In suspected retroperitoneal fibrosis, order IgG4 levels, ESR/CRP, and cross-sectional imaging showing periaortic soft tissue encasing ureters; biopsy confirms.

Step 3 management: Always assess split renal function before considering nephrectomy or aggressive intervention on a chronically obstructed kidney.

Risk Stratification and First-Line Management Logic

1. Is there infection above the obstruction? (fever, leukocytosis, pyuria, sepsis) → emergent decompression within hours

2. Is there severe hyperkalemia, acidosis, uremia, or volume overload? → dialysis indications regardless of decompression timing

3. Is the obstruction bilateral or in a solitary/transplant kidney? → decompression urgent (within 24 h)

4. Is the obstruction unilateral with normal contralateral kidney? → semi-elective (days), but treat pain and prevent infection

— Bladder outlet: Foley catheter; if unable to pass, suprapubic catheter

— Ureteral: Retrograde ureteral stent (cystoscopy) or percutaneous nephrostomy (IR)

— Renal pelvis/UPJ: Percutaneous nephrostomy preferred

— Stent: Less invasive, internal, ideal for stones and benign strictures, requires general anesthesia and ability to traverse obstruction retrograde

— Nephrostomy: Preferred in infected obstruction, malignant obstruction with distorted anatomy, pregnancy, coagulopathy, or when stent cannot be placed; allows pressure monitoring and antegrade access

— Calcium gluconate (membrane stabilization), insulin + dextrose, β2-agonist, then K⁺ removal (loop diuretic if making urine, patiromer/SZC, or dialysis)

Immediate triage questions:

Site-based management:

Choosing stent vs. nephrostomy:

Hyperkalemia management (parallel track):

CCS pearl: In obstructive pyelonephritis (fever + hydronephrosis + AKI), the order set is: blood cultures → broad-spectrum antibiotics (piperacillin-tazobactam or ceftriaxone) → emergent urology/IR consult for decompression → IV fluids → ICU if septic. Do not wait for source control before antibiotics, and do not wait for antibiotic response before decompression.

Board pearl: Indications for emergent dialysis (AEIOU)—Acidosis, Electrolytes (K⁺), Ingestion, Overload, Uremia—apply equally to postrenal AKI when decompression cannot be achieved promptly.

Step 3 management: Once decompressed, expect creatinine to fall over 48–72 h; if it doesn't, reassess for ongoing obstruction, ATN superimposed, or alternative etiology.

Pharmacotherapy — Adjunctive Drug Regimens

— First-line: IV ketorolac 15–30 mg or IM (NSAIDs reduce ureteral smooth muscle tone and inflammation)—avoid in AKI with rising creatinine, single kidney, or hypovolemia

— Alternative/adjunct: IV morphine or hydromorphone for severe pain or when NSAIDs contraindicated

— Acetaminophen as adjunct

— Tamsulosin 0.4 mg daily × up to 4 weeks (α1-blocker relaxes distal ureter)

— Counsel on orthostasis, "floppy iris" if cataract surgery planned

— Not indicated for stones <5 mm (usually pass spontaneously) or >10 mm (need intervention)

— α1-blockers (tamsulosin, alfuzosin) start at Foley placement; continue 3–7 days before trial of void

— 5α-reductase inhibitors (finasteride, dutasteride): long-term reduction in prostate volume; takes 3–6 months for effect; reduces PSA by ~50%

— Empirical broad-spectrum for obstructed infection (piperacillin-tazobactam, carbapenem if ESBL risk)

— Tailor to urine and blood culture

— Pre-procedural prophylaxis per AUA guidelines before stent/nephrostomy

— Anticholinergics, opioids (precipitate retention)

— Nephrotoxins (aminoglycosides, IV contrast, NSAIDs if intrinsic damage developing)

— ACEi/ARB held during AKI; resume after recovery

— Replace 50–75% of urine output with 0.45% saline if patient becomes hypovolemic or hyponatremic

— Monitor electrolytes (K⁺, Mg²⁺, phosphate) q6–12 h

— Most diuresis is appropriate (excretion of retained urea/Na/water); do not over-replace

Analgesia for ureteral colic:

Medical expulsive therapy (MET) for distal ureteral stones 5–10 mm:

BPH-related retention:

Antibiotics:

Avoid/reconsider:

Postobstructive diuresis management:

Board pearl: Tamsulosin for MET is the most tested pharmacology in postrenal AKI—know it cold.

Step 3 management: After Foley for BPH retention, start tamsulosin before voiding trial to improve success rate; trial of void in 3–7 days.

Procedural Decompression — Foley, Stents, and Nephrostomy

— First-line for suspected bladder outlet obstruction

— Use 16–18 Fr; if resistance at prostate, try Coudé-tip catheter

— If unable after 2 attempts → urology consult for suprapubic catheter or filiform/follower dilation

— Document pre-drainage residual volume

— Indications: failed urethral catheterization, urethral stricture, urethral trauma (e.g., pelvic fracture with blood at meatus—urethral catheterization contraindicated until retrograde urethrogram)

— Placed by urology under ultrasound guidance

— Placed via cystoscopy by urology

— Indications: ureteral stones, benign strictures, post-surgical leak, malignant compression amenable to stenting

— Complications: stent symptoms (frequency, urgency, hematuria), encrustation if left >3 months, migration, infection

— Placed by interventional radiology under ultrasound/fluoroscopy

— Preferred over stent in: infected obstruction (better drainage of purulent material), pregnancy, coagulopathy (smaller tract), malignant obstruction with distorted bladder anatomy, failed retrograde access

— Allows antegrade pyelography and conversion to internal stent later

— Ureteroscopy with laser lithotripsy (stones <2 cm)

— Shock wave lithotripsy (selected stones)

— Percutaneous nephrolithotomy (stones >2 cm, staghorn)

— TURP or laser prostatectomy for BPH refractory to medical therapy

— Ureteral reimplantation, ileal conduit, urinary diversion for complex strictures or malignancy

Urethral catheterization (Foley):

Suprapubic catheter:

Retrograde ureteral stent (double-J):

Percutaneous nephrostomy tube:

Definitive procedures (after acute decompression):

CCS pearl: When you see fever + flank pain + hydronephrosis, immediate orders include: blood/urine cultures, broad-spectrum antibiotics, IV fluids, urology consult for emergent decompression, and ICU evaluation. Delay in decompression worsens mortality in obstructed urosepsis.

Board pearl: Pelvic fracture + blood at urethral meatus + high-riding prostate = urethral injury—retrograde urethrogram before any catheter; suprapubic if confirmed.

Key distinction: Stent (internal, comfortable, no external bag) vs. nephrostomy (external, drainage bag, larger drainage capacity, better in infection)—both equivalent for sterile obstruction; nephrostomy wins in sepsis.

Special Populations — Elderly and Renal/Hepatic Impairment

— BPH prevalence ~50% by age 60, ~90% by 85; the dominant cause of postrenal AKI

— Polypharmacy review: anticholinergics, opioids, decongestants, antihistamines, TCAs all precipitate retention

— Beers Criteria flags: oxybutynin, diphenhydramine, amitriptyline in older adults

— Atypical presentations: delirium may be the sole manifestation of retention or urosepsis

— Consider pelvic organ prolapse (cystocele, uterine procidentia kinking ureters), pelvic malignancy, fecal impaction

— Atrophic urethritis can mimic urinary symptoms but doesn't cause obstruction

— Small kidneys (<9 cm) and increased echogenicity suggest chronic disease; superimposed AKI may have less reserve

— Hydronephrosis may be subtle if parenchyma is thin

— Recovery after decompression is often incomplete

— Avoid iodinated contrast when possible; use MR urography or non-contrast CT

— Single functioning kidney → any obstruction causes AKI

— Ureteral stricture at uretero-vesical anastomosis is common (~3–5%) within first year

— Lymphocele compression also possible

— Ultrasound with Doppler is first-line; low threshold for percutaneous nephrostomy

— Hepatorenal physiology complicates AKI workup—always rule out postrenal cause before diagnosing HRS

— Avoid NSAIDs entirely; use cautious opioid dosing

— Tense ascites can rarely cause functional ureteral compression

Elderly men:

Elderly women:

CKD baseline:

Post-transplant patients:

Hepatic impairment:

Step 3 management: In any elderly patient with AKI and new confusion, bladder scan and urinalysis are part of the initial delirium workup, not an afterthought.

Board pearl: Hepatorenal syndrome is a diagnosis of exclusion—rule out postrenal AKI with renal ultrasound before initiating midodrine/octreotide or terlipressin.

Key distinction: Acute-on-chronic obstruction in a CKD patient may not fully reverse; counsel on expected creatinine plateau and possible long-term renal replacement therapy.

Special Populations — Pregnancy and Pediatrics

— Physiologic hydronephrosis (R > L) develops by 20 weeks due to gravid uterus and progesterone-mediated ureteral relaxation; rarely causes AKI alone

— Pathologic obstruction: stones (1 in 1500 pregnancies), pyelonephritis, rarely retroperitoneal pathology

— Imaging: renal ultrasound first; if equivocal, MR urography without gadolinium; low-dose CT only if essential

— Avoid NSAIDs (third trimester—premature ductus closure); avoid fluoroquinolones

— Decompression of choice: double-J ureteral stent or percutaneous nephrostomy—both safe; stents require frequent exchange (every 4–6 weeks) due to encrustation in hypercalciuric pregnancy

— Antibiotics for pyelonephritis: ceftriaxone IV; admit threshold low

— Posterior urethral valves (PUV): Most common cause of bladder outlet obstruction in male infants; presents with antenatal hydronephrosis, weak urinary stream, palpable bladder, AKI in neonate; diagnosed by VCUG; treated with cystoscopic valve ablation

— Ureteropelvic junction (UPJ) obstruction: Most common upper-tract obstruction in children; often detected on antenatal ultrasound; managed with pyeloplasty if symptomatic or worsening function on MAG3 renogram

— Vesicoureteral reflux (VUR): Hydronephrosis without true obstruction; diagnosed by VCUG; managed with prophylactic antibiotics or surgical reimplantation

— Ureterocele, ectopic ureter, neurogenic bladder (spina bifida): Other pediatric considerations

Pregnancy:

Pediatrics:

Workup in children: Renal-bladder ultrasound first; VCUG for reflux/PUV; MAG3 renogram for functional assessment; avoid CT contrast when possible

Board pearl: Newborn boy with weak urinary stream, distended bladder, and bilateral hydronephrosis = posterior urethral valves—place urethral catheter for decompression and arrange urgent VCUG and pediatric urology consult.

Step 3 management: In pregnancy with obstructed pyelonephritis, emergent decompression with stent or nephrostomy plus IV antibiotics; obstetric co-management mandatory.

Key distinction: Physiologic hydronephrosis of pregnancy is asymptomatic and bilateral but R > L; pathologic obstruction causes pain, infection, or AKI.

Complications and Adverse Outcomes

— Occurs in ~50% after relief of bilateral or complete obstruction; typically urine output >200 mL/h × 2 h or >3 L/24 h

— Mechanisms: appropriate excretion of retained urea/Na/water (physiologic) vs. pathologic tubular concentrating defect

— Risks: hypovolemia, hyponatremia, hypokalemia, hypomagnesemia, hypocalcemia, hypophosphatemia

— Management: replace 50–75% of urine output with 0.45% NS; q6–12 h electrolytes; do not match output 1:1 (perpetuates diuresis)

— Decompression of chronically distended bladder can cause mucosal bleeding

— Usually self-limited; clamping the Foley intermittently is not recommended—drain completely

— Obstructed pyelonephritis carries mortality 25–60% without timely decompression

— Continued bacteremia until source controlled

— Pressure-induced tubular atrophy, interstitial fibrosis, irreversible loss of nephrons

— Permanent CKD risk increases with duration >2 weeks

— From sepsis, hypotension, or contrast during workup

— Prolongs recovery beyond simple decompression

— Rare; chronic massive distension can cause spontaneous rupture

— Infection, dislodgment, encrustation, bleeding, perforation

— Forgotten stents are a malpractice flashpoint—always document removal/exchange schedule

— Chronic obstruction impairs distal tubular function; may persist post-relief

Postobstructive diuresis:

Hematuria ex vacuo:

Urosepsis:

Renal parenchymal injury:

Acute tubular necrosis (superimposed):

Bladder rupture:

Stent/nephrostomy complications:

Distal RTA, nephrogenic diabetes insipidus:

Step 3 management: After decompression, monitor urine output hourly for first 24 h; daily weights, q6–12 h electrolytes; cautious fluid replacement to avoid perpetuating diuresis.

Board pearl: Postobstructive diuresis with rising serum sodium and worsening pre-renal indices = over-diuresis; reduce replacement rate. With falling sodium = inappropriate replacement with hypotonic fluid—switch to isotonic.

CCS pearl: Document a stent removal/exchange plan at discharge; ureteral stents must be exchanged every 3 months or removed to prevent encrustation, stone formation, and obstruction.

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Inability to pass urethral catheter

— Suspected urethral injury (pelvic fracture, blood at meatus)

— Obstructed urosepsis

— Bilateral hydronephrosis on imaging

— Solitary kidney with obstruction

— Pediatric obstruction (PUV, severe UPJ)

— Need for percutaneous nephrostomy (sepsis, failed retrograde access, pregnancy with coagulopathy)

— AKI requiring dialysis (AEIOU criteria)

— Severe electrolyte derangements

— Diagnostic uncertainty between postrenal, intrinsic, and prerenal

— Post-decompression failure to recover

— Septic shock from urosepsis (lactate >4, vasopressors, MAP <65 despite fluids)

— Severe hyperkalemia with ECG changes

— Severe metabolic acidosis (pH <7.2) refractory to bicarbonate

— Hemodynamic instability during/after decompression

— Need for continuous renal replacement therapy

— AKI with creatinine >2× baseline

— Need for IV antibiotics, decompression, or pain control

— Postobstructive diuresis requiring monitoring

— Comorbidities limiting outpatient management

— Unilateral hydronephrosis from a small passing stone with normal contralateral kidney, normal creatinine, controlled pain → discharge with urology follow-up in 1–2 weeks

— BPH with mild retention, normal creatinine, successful trial of catheter → discharge with α-blocker and urology follow-up

Emergent urology consultation (call from ED):

Emergent interventional radiology consultation:

Nephrology consultation:

ICU admission criteria:

Inpatient floor admission (most cases):

Outpatient management considerations:

CCS pearl: Move location to ICU when patient develops vasopressor requirement, requires emergent dialysis, or has airway/breathing concerns. Move to floor after decompression and stabilization. Move to clinic only after creatinine trending down and urine output adequate.

Step 3 management: Always specify in handoff: degree of decompression achieved, stent/nephrostomy presence with exchange/removal date, expected follow-up imaging, and antibiotic plan.

Key Differentials — Same-Category (Obstructive) Causes

— Urethra: stricture (instrumentation, STI, lichen sclerosus), posterior urethral valves (pediatric), trauma, foreign body, urethral cancer

— Bladder neck/prostate: BPH, prostate cancer, prostatitis, bladder neck contracture

— Bladder: stones, blood clots (clot retention), tumor (transitional cell carcinoma), neurogenic bladder (functional)

— Ureter (intrinsic): stones (calcium oxalate most common), urothelial cancer, blood clots, sloughed papilla, fungal ball, stricture (post-radiation, post-surgical, TB)

— Ureter (extrinsic): pelvic malignancy (cervical, prostate, bladder, colorectal), retroperitoneal fibrosis, retroperitoneal lymphadenopathy, AAA, pregnancy, endometriosis, iatrogenic ligation

— Renal pelvis/UPJ: stones, UPJ obstruction (congenital), tumor

— Acute, painful, unilateral: stone is overwhelmingly likely

— Subacute, painless, bilateral: malignancy or retroperitoneal fibrosis

— Chronic, intermittent, anuria-polyuria: intermittent obstruction (mobile stone, ball-valve tumor)

— Post-surgical (gyn or colorectal): ureteral injury (ligation, transection) → presents days later with flank pain, urinoma, or AKI

— Neurogenic bladder (diabetes, MS, spinal cord injury)

— Medication-induced retention

— Detrusor-sphincter dyssynergia

By anatomic level:

By etiology pattern:

Functional ("pseudo-obstructive"):

Board pearl: Sloughed renal papillae → ureteral obstruction occurs in diabetes, sickle cell, analgesic nephropathy, pyelonephritis (DSAP mnemonic).

Key distinction: Retroperitoneal fibrosis may present with minimal hydronephrosis because ureters are encased and cannot dilate—MRI/CT reveals periaortic soft tissue mantle.

Step 3 management: Always ask about recent pelvic or abdominal surgery in any AKI workup—iatrogenic ureteral ligation is missed if not specifically sought, and early recognition (within 1 week) allows simple stent placement vs. complex reimplantation later.

Key Differentials — Other-Category (Non-Obstructive) Causes of AKI

— Volume depletion, heart failure, cirrhosis, sepsis (pre-vasodilation phase), NSAIDs, ACEi/ARB

— BUN:Cr >20:1, FeNa <1%, FeUrea <35%, bland sediment

— Responds to volume resuscitation (or treatment of underlying low-flow state)

— Acute tubular necrosis (ATN): ischemic (prolonged prerenal), nephrotoxic (aminoglycosides, contrast, myoglobin, hemoglobin); muddy brown casts, FeNa >2%

— Acute interstitial nephritis (AIN): drug-induced (NSAIDs, PPIs, β-lactams, sulfonamides); fever, rash, eosinophilia, WBC casts, eosinophiluria (low sensitivity); biopsy confirmatory

— Glomerulonephritis: RBC casts, dysmorphic RBCs, proteinuria; serologies (ANCA, anti-GBM, complements, ANA, ASO, hepatitis)

— Vascular: thrombotic microangiopathy (TTP/HUS), atheroembolic disease (post-catheterization, livedo, eosinophilia, blue toes), renal artery stenosis with bilateral disease

— Imaging (renal ultrasound) is the single most useful test—hydronephrosis points to postrenal; bland sediment + no hydronephrosis suggests prerenal or early ATN; active sediment (casts, dysmorphic RBCs) suggests intrinsic

— Bladder scan identifies retention

— Urinalysis sediment is critical—postrenal sediment is usually bland unless infection or stone causes hematuria

Prerenal AKI:

Intrinsic AKI:

How to differentiate from postrenal:

Board pearl: AKI workup mnemonic—"Always rule out postrenal first": bladder scan + renal ultrasound take minutes, are non-invasive, and identify a fully reversible cause. Failing to do this is the most common Step 3 trap.

Key distinction: A patient with HF on diuretics who develops AKI may have prerenal AKI plus unrecognized postrenal AKI from BPH—both can coexist. Imaging confirms.

Step 3 management: When AKI does not improve with volume resuscitation and there is no obvious nephrotoxin, repeat the renal ultrasound before pursuing biopsy.

Secondary Prevention, Discharge Medications, and Long-Term Plan

— α1-blocker (tamsulosin 0.4 mg daily) indefinitely or until definitive therapy

— Consider 5α-reductase inhibitor if prostate >40 g (synergistic with α-blocker per MTOPS trial)

— Discuss surgical options (TURP, laser enucleation, prostatic urethral lift, water vapor therapy) if recurrent retention or failed medical therapy

— Avoid anticholinergics, decongestants, and unnecessary opioids

— 24-hour urine collection for metabolic workup (after recovery, ~6 weeks post-event): calcium, oxalate, citrate, uric acid, sodium, volume, pH

— Counsel fluid intake to achieve >2.5 L urine/day

— Dietary: low sodium (<2.3 g/day), normal calcium (1000–1200 mg/day from diet, not low-calcium), moderate animal protein, low oxalate if hyperoxaluria

— Thiazide for hypercalciuria, potassium citrate for hypocitraturia or uric acid stones, allopurinol for hyperuricosuria

— Long-term stent (exchange every 3 months) or nephrostomy

— Coordinate oncology, palliative care, urology

— Goals-of-care discussion: when to stop exchanging stents

— Glucocorticoids (prednisone 40–60 mg/day taper) ± tamoxifen or methotrexate

— Monitor with serial imaging and creatinine

— Clean intermittent catheterization (CIC) is preferred over chronic indwelling Foley to reduce infection risk

— Anticholinergics or β3-agonists (mirabegron) for detrusor overactivity once outlet is managed

BPH-related retention:

Nephrolithiasis:

Malignant obstruction:

Retroperitoneal fibrosis:

Neurogenic bladder:

Step 3 management: Always document the stent or nephrostomy exchange date at discharge and ensure follow-up is booked before leaving the hospital—forgotten stents cause obstruction, stones, and lawsuits.

Board pearl: Post-stone counseling = hydration, low salt, normal calcium. Low-calcium diets paradoxically increase stone risk by raising oxalate absorption.

Key distinction: Chronic indwelling Foley is associated with bacteriuria within days and increases CAUTI/sepsis risk—CIC is preferred whenever feasible.

Follow-Up, Monitoring Parameters, and Counseling

— BMP at 48–72 h, 1 week, 2 weeks, and 4 weeks until creatinine plateaus

— Urinalysis at 1–2 weeks to assess for residual infection or proteinuria

— Document baseline creatinine for future reference

— Repeat renal ultrasound in 4–6 weeks to confirm resolution of hydronephrosis

— CT or MR urography if persistent symptoms, hematuria, or concern for missed malignancy

— Pre-procedure imaging before stent exchange

— Within 1–2 weeks for stone disease, BPH, stent management

— Stent exchange every 3 months for chronic indwelling stents

— Voiding trial 3–7 days after Foley placement for retention

— Recommended if creatinine does not return to baseline within 4 weeks

— CKD staging and longitudinal management

— Hydration (>2.5 L/day for stone formers)

— Dietary counseling per stone type

— Medication review at every visit—flag anticholinergics, decongestants, opioids in retention-prone patients

— Smoking cessation (bladder cancer risk)

— Pelvic floor therapy if appropriate

— Fever, flank pain, decreased urine output, gross hematuria, inability to void, suprapubic pain

— Worsening leg swelling, shortness of breath (volume overload)

Post-discharge labs:

Imaging follow-up:

Urology follow-up:

Nephrology follow-up:

Lifestyle and counseling:

Symptoms to return for:

Step 3 management: Schedule a single multi-disciplinary follow-up combining urology and primary care within 2 weeks of discharge for complex cases—this is the kind of care coordination Step 3 rewards.

Board pearl: A persistent dilated renal pelvis on follow-up ultrasound after relief is not necessarily ongoing obstruction—MAG3 diuretic renogram distinguishes residual non-obstructive dilation from true obstruction.

CCS pearl: Always order "patient education" on hydration, medication review, and warning signs in the discharge planning sequence.

Ethical, Legal, and Patient Safety Considerations

— Foley insertion is usually implied consent in emergencies, but elective stent or nephrostomy requires explicit consent with discussion of risks (bleeding, infection, perforation, stent symptoms, need for repeat procedures), benefits, and alternatives

— Capacity assessment for elderly patients with delirium—if uremic encephalopathy impairs capacity, proceed under emergency consent or with surrogate decision-maker; document carefully

— Indwelling stents must be exchanged every 3 months; encrustation creates a non-removable stent, recurrent obstruction, and stone burden

— Best practice: stent registry, automated EHR reminders, mandatory exchange date documentation at insertion, patient-held stent card

— Recognized post-operative ureteral injury requires honest disclosure to the patient and family per ethical obligations of transparency

— Early recognition (<1 week) allows simple stent; delayed recognition leads to complex reimplantation or nephrectomy

— Risk management notification per institutional policy

— Malignant obstruction in a patient with advanced cancer raises the question: should we decompress?

— Discuss prognosis, expected benefit (days vs. months of survival), procedural burden (recurrent exchanges), and patient values

— Palliative care consultation appropriate

— Suspected non-accidental trauma (urethral injury in a child) → child protective services

— Sexual assault with urethral/genital injury → forensic protocols, law enforcement reporting per jurisdiction

— Discharge with stent or nephrostomy carries high risk of follow-up failure—ensure urology appointment is scheduled and confirmed before discharge

— Use teach-back to confirm patient understanding of stent symptoms vs. complications requiring ED return

Informed consent for decompression:

Forgotten stent—a major patient safety event:

Iatrogenic ureteral injury:

End-of-life and goals of care:

Mandatory reporting:

Transitions of care:

Step 3 management: When elderly patients with severe BPH-related retention also have advanced dementia and poor functional status, a goals-of-care conversation about chronic catheterization vs. surgical intervention vs. comfort measures is appropriate—involve family and palliative care.

Board pearl: Never confirm a stent removal date without documenting it in the chart and giving the patient a written reminder; this is the single most preventable cause of urologic harm.

High-Yield Associations and Rapid-Fire Clinical Facts

— Calcium oxalate (most common, radiopaque)

— Uric acid (radiolucent, acidic urine; treat with alkalinization)

— Struvite (infection stones, Proteus/Klebsiella/Pseudomonas; staghorn calculi; alkaline urine)

— Cystine (rare, hexagonal crystals, hereditary cystinuria)

DSAP papillary necrosis: Diabetes, Sickle cell, Analgesic nephropathy, Pyelonephritis—causes ureteral obstruction from sloughed papillae

Retroperitoneal fibrosis associations: IgG4-related disease, methysergide (historical), ergot alkaloids, β-blockers, hydralazine, asbestos, malignancy; treated with steroids

Pelvic malignancy → bilateral hydronephrosis: Cervical cancer (most classic), prostate, bladder, colorectal, lymphoma

Pregnancy: Right hydronephrosis > left after 20 weeks (sigmoid cushions left ureter); physiologic, painless

Stone composition pearls:

BPH facts: Prostate growth begins ~age 40; α1A receptor predominates in prostate stroma; tamsulosin is selective

Posterior urethral valves: Male infants, antenatal hydronephrosis, weak stream; VCUG diagnostic

Postobstructive diuresis: Replace 50–75% of urine output with 0.45% NS

Forgotten stent: Exchange every 3 months

Suprapubic catheter: Mandatory if pelvic fracture + blood at meatus; do retrograde urethrogram first

MAG3 renogram with furosemide: Distinguishes obstructive from non-obstructive hydronephrosis

Tamsulosin side effects: Orthostasis, retrograde ejaculation, intraoperative floppy iris syndrome (warn cataract surgeon)

Hydronephrosis grade: Mild (calyceal blunting), moderate (calyceal flattening), severe (parenchymal thinning)

Anuria DDx: Complete bilateral obstruction, severe ATN, bilateral renal artery occlusion, rapidly progressive GN, cortical necrosis—always rule out obstruction first with bladder scan

Board pearl: Anuria in a hospitalized patient = check the Foley first (kinked, clogged, or displaced)—the single most common cause of "anuria" on Step 3 inpatient stems.

Step 3 management: In any AKI of unclear etiology, the first three orders are: BMP, urinalysis with microscopy, and renal/bladder ultrasound (or bladder scan).

Board Question Stem Patterns

Stem 1: 78-year-old man with progressive nocturia, weak stream, and confusion presents with Cr 4.2 (baseline 1.0). Suprapubic dullness palpable. → Answer: Place urethral Foley catheter (bladder outlet obstruction from BPH).

Stem 2: 52-year-old woman with cervical cancer, weight loss, and bilateral flank discomfort. Cr 3.8. Ultrasound shows bilateral hydronephrosis. → Answer: Bilateral percutaneous nephrostomy (ureteral encasement by tumor).

Stem 3: 65-year-old man, day 3 post pelvic fracture from MVC. Blood at urethral meatus, high-riding prostate, distended bladder. → Answer: Retrograde urethrogram first, not Foley; suprapubic catheter if injury confirmed.

Stem 4: 30-year-old pregnant woman at 24 weeks with fever, right flank pain, Cr 2.1, hydronephrosis. → Answer: IV ceftriaxone + percutaneous nephrostomy or ureteral stent; emergent decompression.

Stem 5: 70-year-old diabetic man, recurrent UTIs, fever, flank pain, Cr 3.5, ultrasound with hydronephrosis and gas in collecting system. → Answer: Emphysematous pyelitis; broad-spectrum antibiotics + emergent percutaneous nephrostomy.

Stem 6: Newborn boy, antenatal bilateral hydronephrosis, palpable bladder, weak stream. → Answer: Posterior urethral valves; place urethral catheter, obtain VCUG, urology consult for valve ablation.

Stem 7: 60-year-old man with prostate cancer, Cr improving from 5 to 2 after bilateral nephrostomy, urine output 400 mL/hour, BP 95/60. → Answer: Postobstructive diuresis; replace 50–75% of urine output with 0.45% NS.

Stem 8: 55-year-old woman with IgG4 elevation, periaortic mass on CT, bilateral ureteral encasement. → Answer: Retroperitoneal fibrosis; stent ureters + glucocorticoids.

Stem 9: 45-year-old woman, day 4 post total hysterectomy, flank pain, Cr 2.5, unilateral hydronephrosis. → Answer: Iatrogenic ureteral injury; urology consult for stent or reimplantation.

Stem 10: Hospitalized patient with Foley, sudden anuria. → Answer: Flush/replace Foley before ordering renal ultrasound.

Board pearl: Step 3 favors the management step (decompression modality, antibiotic choice, fluid replacement strategy) over diagnosis—know the next best step at every clinical decision point.

Step 3 management: When in doubt between stent and nephrostomy, choose nephrostomy if there is infection, distorted anatomy, pregnancy, or coagulopathy; choose stent for sterile stone disease.

One-Line Recap

Postrenal AKI is rapidly reversible mechanical obstruction of urinary outflow that must be excluded first in every AKI workup with a bladder scan and renal ultrasound, then decompressed promptly—urgently in the setting of infection, bilateral disease, or a solitary kidney—using Foley, ureteral stent, or percutaneous nephrostomy as anatomy and infection dictate, followed by vigilant monitoring for postobstructive diuresis and structured follow-up to address the underlying cause and prevent recurrence.

Diagnosis: Bladder scan + renal ultrasound first; hydronephrosis defines the level; bland sediment is typical; PVR >300 mL or hydronephrosis confirms.

Decompression hierarchy: Foley for bladder outlet → suprapubic if urethral injury or failed Foley → ureteral stent for sterile ureteral obstruction → percutaneous nephrostomy for infected obstruction, pregnancy, coagulopathy, or distorted anatomy.

Emergent triggers: Fever + hydronephrosis (urosepsis), bilateral obstruction, solitary kidney obstruction, severe hyperkalemia, or refractory acidosis—all warrant immediate decompression and/or dialysis.

Long-term care: Treat the cause (α-blocker for BPH, MET for stones, steroids for retroperitoneal fibrosis, oncologic care for malignancy), document stent exchange schedule, watch for postobstructive diuresis, and book multidisciplinary follow-up before discharge.

Step 3 management: The single most preventable Step 3 error in AKI is failing to rule out postrenal causes—bladder scan and ultrasound take minutes and may obviate any other workup. The second most preventable error is the forgotten ureteral stent—always document exchange date and ensure follow-up is booked.